OBJECTIVES: To evaluate treatment patterns in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) in the United States (US).

METHODS: A retrospective cohort study was conducted using a US claims databaset (Komodo Health closed claims, Jan 2016 – Dec 2020). Patients with CIDP were selected based on presence of: (1) ≥2 claims with CIDP diagnosis, ≥30-≤365 days apart (first considered as index date), (2) ≥1 nerve conduction test present either after the index date and before another CIDP diagnosis, or ≤90 days before the index date, (3) continuous enrollment ±1 year pre- and post-index date. CIDP treatments were evaluated during year 1 post-index. Among patients receiving immunoglobulin (IG), those with ≥8 IG episodes (defined as clusters of IG infusions ≤5 days apart) were considered chronic IG users, while others were considered intermittent users.

RESULTS: Overall, 3409 patients with CIDP were identified. Among them, the most common CIDP treatments used during year 1 post-index were corticosteroids (used at least once by 59% [n=2017] of patients) followed by IG (used at least once by 53% [n=1803] of patients). Among the 1803 patients who received IG in year 1, 62% (n=1113) were chronic IG users, and 38% (n=690) were intermittent IG users. A larger proportion of chronic IG users received other concomitant treatments compared with intermittent IG users (n=568/1113, 51% vs. n=272/690, 39%), which were most commonly OCS (n=354/1113, 32% vs. n=140/690, 20%).

CONCLUSIONS: Among patients with CIDP, IG and OCS were the most common treatments in year 1 post-diagnosis. As a substantial proportion of patients used IG chronically and in combination with steroids, high treatment burden and potential unmet need may remain with current standard of care.